Drug Profile
Research programme: antifibrotic monoclonal antibodies - Sorrento Therapeutics
Alternative Names: WISP1 immunotherapyLatest Information Update: 28 Sep 2018
Price :
$50
*
At a glance
- Originator Sorrento Therapeutics
- Developer Comprehensive Pneumology Center; Sorrento Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action WISP1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for research development in Idiopathic-pulmonary-fibrosis in Germany (Parenteral)
- 28 Sep 2018 No recent reports of development identified for research development in Idiopathic-pulmonary-fibrosis in USA (Parenteral)
- 26 Aug 2014 Sorrento Therapeutics receives SBIR grant from US National Institutes of Health for Monoclonal antibody development in Idiopathic pulmonary fibrosis